Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Asthma (Moderate to Severe) – How Can Novel Biologics Targeting Niche Populations Maximize Uptake in an Increasingly Competitive Marketplace? | Decision Base | US/EU5 | 2015
How Can Novel Biologics Targeting Niche Populations Maximize Uptake in an Increasingly Competitive Marketplace? Although several effective anti-inflammatory agents and bronchodilators are…
Alzheimer’s Disease (Mild to Moderate) – Amid Substantial Unmet Need, What Clinical Improvements Do Neurologists and Payers Expect of Novel Symptomatic and First-to-Market Disease-Modifying Therapies? | Decision Base | US/EU5 | 2015
Amid Substantial Unmet Need, What Clinical Improvements Do Neurologists and Payers Expect of Novel Symptomatic and First-to-Market Disease-Modifying Therapies? Alzheimer’s disease (AD) will…
What Are the U.S. Market Access and Prescribing Hurdles for the Oral Therapies Looming Large on the Horizon for Atherothrombotic Diseases? | Physician & Payer Forum | US | 2015
A Survey of Non-interventional Cardiologists and Managed Care Organization Pharmacy and Medical Directors Atherosclerosis refers to the thickening of arterial walls due to deposition of plaque;…
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (First Line) | Decision Base | US | 2015
What Key Attributes Do Oncologists and Payers Believe Will Differentiate Emerging Therapies? The first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) market is becoming…
Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | DecisionBase | US | 2015
What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Increasingly Competitive Market? In recent years, several new, high-priced…
